Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas

G. Santini, A. M. Congiu, S. Nati, G. Marino, V. Nardi, M. Spriano, R. Vimercati, A. Rubagotti, C. A. Souza

Research output: Contribution to journalArticle

Abstract

Autologous stem cell transplantation (ASCT) has been seen to overcome resistance, allowing an increase in the dose of available drugs and radiotherapy. Initially used after first-line for relapsed or refractory nonHodgkin's lymphomas (NHL), ASDT has since been used in more favourable clinical conditions such as partial remission (PR), first compléter emission, and as front-line therapy following chemotherapy. High-dose chemotherapy and autologous stem-cell transplantation has now became the standard care for eligible patients with recurrent, chemosensitive aggressive NHL Primary refractory patients and resistant relapsearenot good indicationsand should beconsidered a group eligible for phase II studies. Theremay also bea rolein patients with partially responsivedi sease However new and larger randomised studies are needed to clarify this question. A challenge for lymphoma management is the evaluation of the role of high-dose therapy and ASCT as an initial treatment in aggressive NHL, identifying patients who will not becured with standard therapy. A series of concurrent or retrospective analysis would indicate so-called "higherrisk patients", as defined by the IPI, as potential targets for intensified therapy. However, according to published data, the problem remains open to debate. Larger, randomised studies are necessary and welcome and this should be considered a high priority.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalRevista Brasileira de Hematologia e Hemoterapia
Volume24
Issue number2
Publication statusPublished - 2002

Fingerprint

Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Therapeutics
Drug Therapy
Lymphoma
Patient Care
Radiotherapy
Pharmaceutical Preparations

Keywords

  • Autologous stem cell transplantation
  • Non-Hodgkin's lymphomas

ASJC Scopus subject areas

  • Hematology

Cite this

Santini, G., Congiu, A. M., Nati, S., Marino, G., Nardi, V., Spriano, M., ... Souza, C. A. (2002). Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas. Revista Brasileira de Hematologia e Hemoterapia, 24(2), 77-84.

Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas. / Santini, G.; Congiu, A. M.; Nati, S.; Marino, G.; Nardi, V.; Spriano, M.; Vimercati, R.; Rubagotti, A.; Souza, C. A.

In: Revista Brasileira de Hematologia e Hemoterapia, Vol. 24, No. 2, 2002, p. 77-84.

Research output: Contribution to journalArticle

Santini, G, Congiu, AM, Nati, S, Marino, G, Nardi, V, Spriano, M, Vimercati, R, Rubagotti, A & Souza, CA 2002, 'Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas', Revista Brasileira de Hematologia e Hemoterapia, vol. 24, no. 2, pp. 77-84.
Santini G, Congiu AM, Nati S, Marino G, Nardi V, Spriano M et al. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas. Revista Brasileira de Hematologia e Hemoterapia. 2002;24(2):77-84.
Santini, G. ; Congiu, A. M. ; Nati, S. ; Marino, G. ; Nardi, V. ; Spriano, M. ; Vimercati, R. ; Rubagotti, A. ; Souza, C. A. / Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas. In: Revista Brasileira de Hematologia e Hemoterapia. 2002 ; Vol. 24, No. 2. pp. 77-84.
@article{69e6ca7940674b5fbc6d1f7b0dc27b7e,
title = "Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas",
abstract = "Autologous stem cell transplantation (ASCT) has been seen to overcome resistance, allowing an increase in the dose of available drugs and radiotherapy. Initially used after first-line for relapsed or refractory nonHodgkin's lymphomas (NHL), ASDT has since been used in more favourable clinical conditions such as partial remission (PR), first compl{\'e}ter emission, and as front-line therapy following chemotherapy. High-dose chemotherapy and autologous stem-cell transplantation has now became the standard care for eligible patients with recurrent, chemosensitive aggressive NHL Primary refractory patients and resistant relapsearenot good indicationsand should beconsidered a group eligible for phase II studies. Theremay also bea rolein patients with partially responsivedi sease However new and larger randomised studies are needed to clarify this question. A challenge for lymphoma management is the evaluation of the role of high-dose therapy and ASCT as an initial treatment in aggressive NHL, identifying patients who will not becured with standard therapy. A series of concurrent or retrospective analysis would indicate so-called {"}higherrisk patients{"}, as defined by the IPI, as potential targets for intensified therapy. However, according to published data, the problem remains open to debate. Larger, randomised studies are necessary and welcome and this should be considered a high priority.",
keywords = "Autologous stem cell transplantation, Non-Hodgkin's lymphomas",
author = "G. Santini and Congiu, {A. M.} and S. Nati and G. Marino and V. Nardi and M. Spriano and R. Vimercati and A. Rubagotti and Souza, {C. A.}",
year = "2002",
language = "English",
volume = "24",
pages = "77--84",
journal = "Revista Brasileira de Hematologia e Hemoterapia",
issn = "1516-8484",
publisher = "Sociedade Brasileira de Hematologia e Hemoterapia",
number = "2",

}

TY - JOUR

T1 - Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas

AU - Santini, G.

AU - Congiu, A. M.

AU - Nati, S.

AU - Marino, G.

AU - Nardi, V.

AU - Spriano, M.

AU - Vimercati, R.

AU - Rubagotti, A.

AU - Souza, C. A.

PY - 2002

Y1 - 2002

N2 - Autologous stem cell transplantation (ASCT) has been seen to overcome resistance, allowing an increase in the dose of available drugs and radiotherapy. Initially used after first-line for relapsed or refractory nonHodgkin's lymphomas (NHL), ASDT has since been used in more favourable clinical conditions such as partial remission (PR), first compléter emission, and as front-line therapy following chemotherapy. High-dose chemotherapy and autologous stem-cell transplantation has now became the standard care for eligible patients with recurrent, chemosensitive aggressive NHL Primary refractory patients and resistant relapsearenot good indicationsand should beconsidered a group eligible for phase II studies. Theremay also bea rolein patients with partially responsivedi sease However new and larger randomised studies are needed to clarify this question. A challenge for lymphoma management is the evaluation of the role of high-dose therapy and ASCT as an initial treatment in aggressive NHL, identifying patients who will not becured with standard therapy. A series of concurrent or retrospective analysis would indicate so-called "higherrisk patients", as defined by the IPI, as potential targets for intensified therapy. However, according to published data, the problem remains open to debate. Larger, randomised studies are necessary and welcome and this should be considered a high priority.

AB - Autologous stem cell transplantation (ASCT) has been seen to overcome resistance, allowing an increase in the dose of available drugs and radiotherapy. Initially used after first-line for relapsed or refractory nonHodgkin's lymphomas (NHL), ASDT has since been used in more favourable clinical conditions such as partial remission (PR), first compléter emission, and as front-line therapy following chemotherapy. High-dose chemotherapy and autologous stem-cell transplantation has now became the standard care for eligible patients with recurrent, chemosensitive aggressive NHL Primary refractory patients and resistant relapsearenot good indicationsand should beconsidered a group eligible for phase II studies. Theremay also bea rolein patients with partially responsivedi sease However new and larger randomised studies are needed to clarify this question. A challenge for lymphoma management is the evaluation of the role of high-dose therapy and ASCT as an initial treatment in aggressive NHL, identifying patients who will not becured with standard therapy. A series of concurrent or retrospective analysis would indicate so-called "higherrisk patients", as defined by the IPI, as potential targets for intensified therapy. However, according to published data, the problem remains open to debate. Larger, randomised studies are necessary and welcome and this should be considered a high priority.

KW - Autologous stem cell transplantation

KW - Non-Hodgkin's lymphomas

UR - http://www.scopus.com/inward/record.url?scp=52649149930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649149930&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 77

EP - 84

JO - Revista Brasileira de Hematologia e Hemoterapia

JF - Revista Brasileira de Hematologia e Hemoterapia

SN - 1516-8484

IS - 2

ER -